BACKGROUND:Glatiramer acetate (GA, Copaxone) has beneficial effects on the clinical course of relapsing-remitting multiple sclerosis (RRMS). However, the exact molecular mechanisms of GA effects are only partially understood. OBJECTIVE: To characterized GA molecular effects in RRMS patients within 3 months of treatment by microarray profiling of peripheral blood mononuclear cells (PBMC). METHODS:Gene-expression profiles were determined in RRMS patients before and at 3 months after initiation of GA treatment using Affimetrix (U133A-2) microarrays containing 14,500 well-characterized human genes. Most informative genes (MIGs) of GA-induced biological convergent pathways operating in RRMS were constructed using gene functional annotation, enrichment analysis and pathway reconstruction bioinformatic softwares. Verification at the mRNA and protein level was performed by qRT-PCR and FACS. RESULTS:GA induced a specific gene expression molecular signature that included altered expression of 480 genes within 3 months of treatment; 262 genes were up-regulated, and 218 genes were down-regulated. The main convergent mechanisms of GA effects were related to antigen-activated apoptosis, inflammation, adhesion, and MHC class-I antigen presentation. CONCLUSIONS: Our findings demonstrate that GA treatment induces alternations of immunomodulatory gene expression patterns that are important for suppression of disease activity already at three months of treatment and can be used as molecular markers of GA activity.
RCT Entities:
BACKGROUND:Glatiramer acetate (GA, Copaxone) has beneficial effects on the clinical course of relapsing-remitting multiple sclerosis (RRMS). However, the exact molecular mechanisms of GA effects are only partially understood. OBJECTIVE: To characterized GA molecular effects in RRMS patients within 3 months of treatment by microarray profiling of peripheral blood mononuclear cells (PBMC). METHODS: Gene-expression profiles were determined in RRMS patients before and at 3 months after initiation of GA treatment using Affimetrix (U133A-2) microarrays containing 14,500 well-characterized human genes. Most informative genes (MIGs) of GA-induced biological convergent pathways operating in RRMS were constructed using gene functional annotation, enrichment analysis and pathway reconstruction bioinformatic softwares. Verification at the mRNA and protein level was performed by qRT-PCR and FACS. RESULTS:GA induced a specific gene expression molecular signature that included altered expression of 480 genes within 3 months of treatment; 262 genes were up-regulated, and 218 genes were down-regulated. The main convergent mechanisms of GA effects were related to antigen-activated apoptosis, inflammation, adhesion, and MHC class-I antigen presentation. CONCLUSIONS: Our findings demonstrate that GA treatment induces alternations of immunomodulatory gene expression patterns that are important for suppression of disease activity already at three months of treatment and can be used as molecular markers of GA activity.
Authors: Sara J Ireland; Alyssa A Guzman; Dina E O'Brien; Samuel Hughes; Benjamin Greenberg; Angela Flores; Donna Graves; Gina Remington; Elliot M Frohman; Laurie S Davis; Nancy L Monson Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Jody Corey-Bloom; Alaina M Aikin; Ashley M Gutierrez; Jwan S Nadhem; Taylor L Howell; Elizabeth A Thomas Journal: Brain Res Date: 2017-08-18 Impact factor: 3.252
Authors: M Pazhouhandeh; M-A Sahraian; S D Siadat; A Fateh; F Vaziri; F Tabrizi; F Ajorloo; A K Arshadi; E Fatemi; S Piri Gavgani; F Mahboudi; F Rahimi Jamnani Journal: Clin Exp Immunol Date: 2018-01-25 Impact factor: 4.330
Authors: Josephine D Alessandro; Kevin Garofalo; Ganlin Zhao; Christopher Honan; Jay Duffner; Ishan Capila; Ian Fier; Ganesh Kaundinya; Daniel Kantor; Tanmoy Ganguly Journal: CNS Neurol Disord Drug Targets Date: 2017 Impact factor: 4.388
Authors: Madhan Thamilarasan; Michael Hecker; Robert Hermann Goertsches; Brigitte Katrin Paap; Ina Schröder; Dirk Koczan; Hans-Jürgen Thiesen; Uwe Klaus Zettl Journal: J Neuroinflammation Date: 2013-10-17 Impact factor: 8.322